BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Enzon Pharmaceuticals Inc.

Headquarters: Bridgewater, NJ, United States
Year Founded: 1981
Status: Public
Industry Sector: HealthTechnology
CEO: Richard L. Feinstein, CPA
Number Of Employees: N/A
Enterprise Value: $7,208,962
PE Ratio: -4.56
Exchange/Ticker 1: OTCQB:ENZN
Exchange/Ticker 2: N/A
Latest Market Cap: $6,122,700

BioCentury | Jun 14, 2017
Distillery Therapeutics

Neurology

BioCentury | Sep 14, 2015
Finance

Gaining leverage

Reading the tea leaves of Icahn's Vivus debt play
BioCentury | May 13, 2015
Company News

Baxter buys Sigma-Tau leukemia portfolio

BioCentury | May 12, 2014
Company News

Enzon infectious news

BioCentury | Dec 16, 2013
Company News

Hologic diagnostic news

BioCentury | Nov 11, 2013
Company News

Enzon, Santaris deal

BioCentury | Sep 5, 2013
Targets & Mechanisms

lncRNA meets the androgen receptor

BioCentury | Apr 29, 2013
Financial News

Enzon financial update

BioCentury | Apr 29, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones
BioCentury | Apr 24, 2013
Financial News

Enzon to distribute royalty cash through dividends

Items per page:
1 - 10 of 236